Methods for producing AAV hollow particles encapsulating nucleic acids

By preparing and introducing specific linear nucleic acid fragments, nucleic acids are successfully encapsulated in empty AAV particles, solving the problems of low efficiency and insufficient safety in the prior art, and achieving efficient and safe nucleic acid encapsulation and delivery.

CN114269940BActive Publication Date: 2024-12-06NIPPON MEDICAL SCHOOL FOUND +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080061553.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-07-03
Filing Date
2020-07-02
Publication Date
2024-12-06
Estimated Expiration
2040-07-02

AI Technical Summary

Technical Problem

Existing methods for producing empty AAV particles encapsulating nucleic acids have problems of complexity and inefficiency, especially in maintaining initial viral infection activity and safety.

Method used

Ensure the nucleic acid nucleic acid fragments by preparing a linear nucleic acid fragment containing the region A sequence and region D' sequence in the AAV reverse terminal repeat (ITR) and introducing it into the cell to produce empty AAV particles encapsulating the nucleic acid. Effectively encapsulate and maintain infective activity in the granules.

Benefits of technology

A simpler and more efficient generation of empty AAV particles encapsulating nucleic acids is achieved, improving the encapsulation efficiency and safety of nucleic acids, reducing the presence of virus-derived sequences, thereby providing a high safety and target cell-specific delivery system.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114269940B_ABST
    Figure CN114269940B_ABST
Patent Text Reader

Abstract

A method for producing adeno-associated virus (AAV) hollow particles encapsulating nucleic acid, comprising the following steps: (1) preparing a linear nucleic acid fragment comprising an A region sequence and a D' region sequence (i.e., an AD sequence) in an AAV inverted terminal repeat (ITR) or a sequence complementary to the AD sequence, and a target gene sequence; (2) introducing the nucleic acid fragment prepared in step (1) into cells capable of producing AAV hollow particles; and (3) culturing the cells obtained in step (2).
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to methods for producing empty AAV particles encapsulating nucleic acids. Background Art

[0002] Various gene introduction technologies have been developed for introducing and expressing target genes into mammalian cells, tissues, or individuals including humans. One of the technologies is viral vectors. Various vectors derived from lentiviruses, oncorretroviruses, adenoviruses, adeno-associated viruses, and the like are known.

[0003] Among them, adeno-associated virus (AAV) vectors have recently been expected to be useful vectors for gene introduction in gene therapy. AAV is a non-pathogenic virus belonging to Parvoviridae. Because AAV lacks self-renewal ability, AAV cannot grow autonomously, and needs to be co-infected with adenovirus or herpes virus for its growth. Therefore, AAV has low propagation ability. AAV also has low immunogenicity in the host. Due to such characteristics, AAV has the advantage of being highly safe as a vector for gene introduction. In addition, AAV has a wide host range, and therefore various cells can be infected by AAV. Since vectors derived from various AAV serotypes (such as AAV1 to AAV9) have been developed, vectors have been used to introduce genes into specific cells, tissues and organs, such as nerve cells, muscle cells and hepatocytes by utilizing the specificity of target cells infected by each serotype. However, conventional viral vectors including AAV have various problems, including problems about obtaining self-renewal ability and being contaminated by wild-type viruses.

[0004] In order to solve the problems described above, Samulski et al. proposed to prepare a capsid of the outer shell protein constituting AAV, and use the capsid as a drug delivery carrier (Patent Document 1). Although empty AAV particles formed by the capsid and not containing the AAV viral genome have the initial infection activity of the virus, including specific recognition of target cells, adsorption and invasion into cells, and decapsidation, empty AAV particles do not have viral growth activity because they do not have the virus-derived genes required for self-renewal. Therefore, empty particles can specifically deliver drugs such as proteins or nucleic acids to target cells, and are safe for the individuals to whom they are administered, and are carriers for ideal drug delivery systems (DDS: drug delivery systems).

[0005] Samulski et al. proposed a method of introduction, which includes denaturing empty particles in the presence of urea or under heat or pH conditions, incorporating drugs into the interior of the denatured empty particles, and then reconstructing the empty particles (Patent Document 1). However, when the empty particles are treated with denaturants such as urea, the initial infection activity of the capsid is reduced and the function as a delivery carrier is impaired. In addition, Okada et al. disclose a method for introducing proteins or nucleic acids into empty particles, which includes the use of a surfactant (Patent Document 2).

[0006] It is known that during the replication of AAV, the DNA genome may take the form of circular double-stranded DNA (cAAV). This double-stranded DNA has an inverted terminal repeat (ITR) sequence. Musatov et al. have reported that the replication and encapsulation of AAV genomic DNA requires a sequence (AD sequence) consisting of the sequence of region A and the sequence of region D' in the ITR (non-patent document 1). Musatov et al. have disclosed the introduction of circular double-stranded DNA containing the AD sequence into cells to produce empty AAV particles that encapsulate DNA. In addition, Okada et al. have disclosed the introduction of nucleic acid fragments containing the AD sequence and its complementary sequence (sequence of region A' and sequence of region D) into cells to produce empty AAV particles that encapsulate nucleic acid (patent document 3).

[0007] Citation List

[0008] Patent Literature

[0009] Patent Document 1: U.S. Patent No. 5,863,541

[0010] Patent Document 2: WO2012 / 144446

[0011] Patent Document 3: WO2018 / 139637

[0012] Non-patent literature

[0013] Non-patent document 1: Musatov et al., 2002, Vol. 76, No. 24, pp. 12792-12802. Summary of the invention

[0014] Problem that the invention aims to solve

[0015] It is an object of the present invention to develop and provide a simpler and more efficient method for encapsulating nucleic acids into empty particles.

[0016] Means of solving the problem

[0017] As a result of diligent research, the inventor has successfully produced empty particles wherein encapsulated nucleic acid and maintained the initial infection activity of the virus by a simpler and more effective method. In addition, the inventor has found that by mixing the empty particles of the encapsulated nucleic acid with target cells, the nucleic acid encapsulated in the empty particles is effectively introduced into the target cells. The present invention is based on these discoveries and results, and provides the following content.

[0018] That is, the present invention relates to:

[0019] [1] A method for producing adeno-associated virus (AAV) empty particles encapsulating nucleic acid, the method comprising:

[0020] (1) a step of preparing a linear nucleic acid fragment, wherein the linear nucleic acid fragment contains a region A sequence and a region D' sequence (AD sequence) in an AAV inverted terminal repeat (ITR) sequence and / or a complementary sequence of the AD sequence, and a target gene sequence,

[0021] (2) a step of introducing the nucleic acid fragment prepared in step (1) into cells producing empty AAV particles, and

[0022] (3) a step of culturing the cells obtained in step (2);

[0023] [2] The method according to [1], wherein the nucleic acid fragment contains an AD sequence and / or a complementary sequence of the AD sequence, and a target gene sequence in order from the 5' end to the 3' end;

[0024] [3] The method according to [1], wherein the nucleic acid fragment contains the target gene sequence, and the AD sequence and / or the complementary sequence of the AD sequence in order from the 5' end to the 3' end;

[0025] [4] The method according to [1], wherein the nucleic acid fragment does not contain the sequence of region A' in AAV ITR;

[0026] [5] The method according to [1], wherein the step of preparing the nucleic acid fragment comprises amplifying the nucleic acid fragment by a nucleic acid amplification reaction;

[0027] [6] The method according to [1], wherein the cells producing empty particles are cells into which the Cap gene and Rep gene of AAV and the helper functions of AAV have been introduced;

[0028] [7] The method according to [1], wherein the nucleic acid fragment is a double-stranded nucleic acid or a single-stranded nucleic acid;

[0029] [8] The method according to [1], wherein the region of the AD sequence in the nucleic acid fragment is a double-stranded nucleic acid, and the region of the target gene sequence in the nucleic acid fragment is a single-stranded nucleic acid;

[0030] [9] A linear nucleic acid fragment comprising a region A sequence and a region D' sequence (AD sequence) in an AAV inverted terminal repeat (ITR) sequence or a complementary sequence to the AD sequence, and a target gene sequence;

[0031]

[10] The nucleic acid fragment according to [9], which contains an AD sequence or a complementary sequence of the AD sequence, and a target gene sequence in order from the 5' end to the 3' end;

[0032]

[11] The nucleic acid fragment according to [9], which contains the target gene sequence and the AD sequence or the complementary sequence of the AD sequence in order from the 5' end to the 3' end;

[0033]

[12] The nucleic acid fragment according to [9], which does not contain the sequence of region A' in AAV ITR;

[0034]

[13] the nucleic acid fragment of [9], which is a double-stranded nucleic acid or a single-stranded nucleic acid;

[0035]

[14] The nucleic acid fragment according to [9], wherein the AD sequence region is a double-stranded nucleic acid, and the target gene sequence region is a single-stranded nucleic acid;

[0036]

[15] An empty AAV particle encapsulating a nucleic acid, comprising the linear nucleic acid fragment according to any one of [9] to

[14] .

[0037] Effects of the Invention

[0038] The present invention provides a method for more easily and efficiently producing empty particles in which nucleic acids are encapsulated. As used herein, "empty AAV particles encapsulating nucleic acids" means AAV-like particles in which linear nucleic acid fragments are encapsulated and do not carry a complete AAV genome. Empty AAV particles encapsulating nucleic acids are different from ordinary AAV.

[0039] According to the method for producing empty particles of the present invention, compared with conventional methods, the target nucleic acid is more easily and efficiently encapsulated into the empty particles, while reducing the number of virus-derived sequences leading to safety and low cytotoxicity. Therefore, empty particles with high safety and target cell specificity can be provided. BRIEF DESCRIPTION OF THE DRAWINGS

[0040] [ Figure 1 ] Figure 1 Shown are the results of measuring the titer of empty AAV particles prepared using a linear nucleic acid fragment containing the AD sequence.

[0041] [ Figure 2 ] Figure 2 Shown are the results of measuring the titer of empty AAV particles prepared using a linear nucleic acid fragment containing the AD sequence.

[0042] [ Figure 3 ] Figure 3 Shown are the results of measuring gene introduction by empty AAV particles prepared using a linear nucleic acid fragment containing the AD sequence.

[0043] [ Figure 4 ] Figure 4 The ITR regions of AAV are shown.

[0044] [ Figure 5 ] Figure 5 A summary of Examples 1 to 3 is shown.

[0045] [ Figure 6 ] Figure 6 The linear nucleic acid fragments encapsulated in empty AAV particles from Example 4 are shown.

[0046] [ Figure 7 ] Figure 7 Shown are the results of measuring gene introduction by empty AAV particles prepared using a linear nucleic acid fragment containing the AD sequence.

[0047] [ Figure 8 ] Figure 8 The linear nucleic acid fragments encapsulated in empty AAV particles from Example 5 are shown. DETAILED DESCRIPTION

[0048] As used herein, the term "inverted terminal repeat (ITR)" means a cis-element present at both ends of the AAV genomic DNA. ITR is essential for the replication, amplification and packaging of the AAV genomic DNA. ITR contains a Rep binding site (also called RBS or RBE) and a terminal dissociation site (TRS) as well as a palindromic sequence that allows hairpin formation. ITR contains region A, region B, region B', region C, region C' and region A' in sequence from the end. The A region and the A' region, the B region and the B' region, and the C region and the C' region are complementary sequences to each other in opposite directions, and anneal to form a double strand, and thus form a double strand such as Figure 4 The hammerhead structure shown in . Region D is present at one end of the A' region, which is the opposite side (3' end side or 5' end side) of the C' region.

[0049] As used herein, the term "3' end side" is intended to specify a position in the 3' end direction outside the 3' end portion of the sequence (region). Similarly, the term "5' end side" is intended to specify a position in the 5' end direction outside the 5' end portion of the sequence (region). Therefore, the term "3' end side" or "5' end side" in the context means that the target sequence, etc. is positioned adjacent to the 3' or 5' end portion of the sequence (region), or the target sequence, etc. is positioned not adjacent to the 3' or 5' end portion of the sequence (region) [that is, any sequence intervenes between the target sequence, etc. and the 3' or 5' end portion of the sequence (region)].

[0050] As used herein, "capsid" is one of the elements constituting a virus particle (virion), and means a shell or outer shell consisting of a plurality of unit proteins (capsid protein subunits) surrounding a genomic DNA or core. As used herein, particles consisting only of capsid proteins that do not contain viral nucleic acid, core or any other substance in the capsid are referred to as "empty particles" and are sometimes referred to as "empty capsid particles".

[0051] As used herein, "target gene" means any gene that is expected to be encapsulated in empty particles and introduced into target cells. Examples of target genes include structural genes (e.g., genes of functional proteins such as enzymes, transcription factors, reporters, growth factors or antigenic proteins, or fragments thereof) and regulatory genes [e.g., genes encoding antisense DNA, functional RNA (antisense RNA, siRNA, miRNA, ribozymes, etc.). In addition, the target gene may contain regulatory elements that control transcription or translation, such as promoter sequences, enhancer sequences, poly A addition signal sequences, terminator sequences, etc. The target gene may be a sequence that can express a protein or a functional nucleic acid in a cell.

[0052] Hereinafter, the present invention will be described in detail.

[0053] As one embodiment, the present invention provides a method for producing empty AAV particles encapsulating nucleic acid, comprising the following steps:

[0054] (1) a step of preparing a linear nucleic acid fragment, wherein the linear nucleic acid fragment contains a region A sequence and a region D' sequence (AD sequence) in an AAV inverted terminal repeat (ITR) sequence or a complementary sequence to the AD sequence, and a target gene sequence,

[0055] (2) a step of introducing the nucleic acid fragment prepared in step (1) into cells producing empty AAV particles, and

[0056] (3) A step of culturing the cells obtained in step (2).

[0057] (A) Steps for preparing nucleic acid

[0058] The linear nucleic acid fragment in step (1) contains an AD sequence or a complementary sequence of an AD sequence, and a target gene sequence. As an AD sequence, a sequence of a genomic DNA of a known natural AAV serotype (e.g., serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11) can be used. In the ITR of each serotype, region A, region B, region B', region C, region C', and region A' have been identified. Region D is present at one end of the A' region in the ITR, and the A' region is the opposite side (3' end side or 5' end side) of the C' region. The sequence of region D of each serotype has also been identified, as well as the sequence of region D' as a complementary sequence of the region D sequence in the opposite direction. The A region, the A' region, the D region, and the D' region can be derived from different serotypes. In addition, a mutant of the native sequence of the A region can also be used, as long as it retains the ability to bind to Rep and the ability to form a hairpin. In this case, the sequence of the A' region is complementary to the mutant sequence of the A region. Alternatively, a mutant of the native sequence of the D region may be used, and in this case, the sequence of the D′ region is complementary to the mutant sequence of the D region.

[0059] The linear nucleic acid fragment used in the present invention does not contain the sequence of the A' region (SEQ ID NO: 8). In other words, the sequence of the A region contained in the linear nucleic acid fragment does not anneal in the molecule, and therefore the sequence of the A region does not form a secondary structure. In addition, the linear nucleic acid fragment does not contain a sequence consisting of a D region sequence-A' region sequence in the direction from the 5' end to the 3' end. In other words, the AD sequence contained in the linear nucleic acid fragment does not anneal in the molecule, and therefore the AD sequence does not form a secondary structure. Further, the nucleic acid fragment lacks the sequence of at least one region selected from region B, region B', region C and region C'. More preferably, the nucleic acid fragment lacks the sequences of region B, region B', region C and region C'.

[0060] In one aspect of the present invention, the linear nucleic acid fragment in step (1) contains an AD sequence or a complementary sequence of the AD sequence, and a target gene sequence in the direction from the 5' end to the 3' end. In another aspect, the linear nucleic acid fragment contains a target gene sequence and an AD sequence or a complementary sequence of the AD sequence in the direction from the 5' end to the 3' end.

[0061] The linear nucleic acid fragment in step (1) contains the target gene sequence. The target gene may be foreign to AAV.

[0062] The linear nucleic acid fragment in step (1) contains at least one AD sequence or a complementary sequence of an AD sequence. In the present invention, the nucleic acid fragment may contain one AD sequence or a complementary sequence of an AD sequence, two AD sequences or complementary sequences of AD sequences, three AD sequences or complementary sequences of AD sequences, four AD sequences or complementary sequences of AD sequences, or five or more AD sequences or complementary sequences of AD sequences. For example, a nucleic acid fragment containing one, two or three AD sequences or complementary sequences of AD sequences may be used.

[0063] The linear nucleic acid fragment in step (1) is DNA or RNA, preferably DNA. Further, the nucleic acid fragment may be a double-stranded nucleic acid formed by annealing two nucleic acid molecules that are complementary to each other, or may be a single-stranded nucleic acid of one molecule. The term "linear nucleic acid" means that the two ends of the nucleic acid are not bound by a covalent bond. Further, the entire sequence of the nucleic acid fragment may be double-stranded, or part of the sequence of the nucleic acid fragment may be single-stranded, and the remainder of the nucleic acid may be double-stranded. For example, in the nucleic acid fragment, the AD sequence region may be double-stranded, while the region of the target gene sequence may be single-stranded. The nucleic acid fragment may be a nucleic acid fragment that does not have a phosphate bond (nucleotide bond) at one position, two positions, or multiple positions in the double-stranded portion. As one aspect of the present invention, the linear nucleic acid fragment is a double-stranded nucleic acid obtained by annealing the following three molecules: a single-stranded nucleic acid containing a target gene sequence, a single-stranded nucleic acid containing an AD sequence, and a single-stranded nucleic acid complementary to the target gene sequence and the AD sequence. Naturally, the double-stranded nucleic acid containing the AD sequence contains the complementary strand of the AD sequence, and the double-stranded nucleic acid containing the complementary strand of the AD sequence contains the AD sequence.

[0064] The linear nucleic acid fragments in step (1) can be prepared by known nucleic acid preparation methods. Nucleic acid fragments can be prepared in vitro by nucleic acid amplification reactions such as PCR or chemical synthesis. In addition, nucleic acids can be prepared by: producing nucleic acids in vivo, for example in eukaryotic cells and prokaryotic cells, by polymerase reaction, replication and / or transcription, and then purifying nucleic acids from cells. Linear nucleic acid fragments themselves are also included in the present invention as an aspect.

[0065] As one aspect of the present invention, the AD sequence contained in the linear nucleic acid fragment in step (1) is a sequence derived from AAV2, and the sequence of the A region and the sequence of the D' region are shown in SEQ ID NO: 9 and SEQ ID NO: 10, respectively. Further, the sequences of the A' region and the D region from AAV2 are shown in SEQ ID NO: 8 and SEQ ID NO: 11, respectively. Further, the AD sequence from AAV2 is shown in SEQ ID NO: 1, and the complementary sequence of the AD sequence is shown in SEQ ID NO: 18.

[0066] Examples of nucleic acid fragments in step (1) include natural nucleic acids, chemically modified nucleic acids, artificial nucleic acids, nucleic acid analogs, and combinations thereof. Natural nucleic acids are DNA or RNA consisting only of naturally occurring nucleotides connected to each other. Chemically modified nucleic acids are nucleic acids that are artificially chemically modified. Examples of chemically modified nucleic acids include methylphosphonate DNA / RNA, thiophosphate DNA / RNA (PS-DNA / RNA), phosphoramidate DNA / RNA, and 2'-O-methyl DNA / RNA. Artificial nucleic acids are nucleic acids that partially contain non-natural nucleotides in naturally occurring nucleic acids, or nucleic acids that are only composed of non-natural nucleotides connected to each other. As used herein, the term "non-natural nucleotides" refers to artificially constructed or artificially chemically modified nucleotides that do not exist in nature and have properties and / or structures similar to naturally occurring nucleotides. Nucleic acid analogs are artificially constructed macromolecular compounds that have structures and / or properties similar to naturally occurring nucleic acids. Examples of nucleic acid analogs include peptide nucleic acids (PNA), peptide nucleic acids with phosphate groups (PHONA), 2'-F, 2'-O-methyl (2'-OMe), 2'-O-methoxyethyl (2'-MOE), bridged nucleic acids and morpholino nucleic acids (including morpholino oligomers). Examples of bridged nucleic acids include bridged nucleic acids and / or locked nucleic acids (BNA / LNA), and ENA (2'-O, 4'-C-ethyl-BNA). As one aspect of the present invention, in the nucleic acid fragment, the region of the AD sequence or the complementary sequence region of the AD sequence is a naturally occurring nucleic acid, and the region of the target gene sequence is an artificial nucleic acid.

[0067] In nucleic acid, when necessary, its phosphate group, sugar and / or base can be marked. As a label, a labeling substance known in the art can be used. The example of labeling substance includes radioisotope (for example, 32P, 3H, 14C), DIG, biotin, fluorescent dye (for example, FITC, Texas, cy3, cy5, cy7, FAM, HEX, VIC, JOE, Rox, TET, Bodypy 493, NBD, TAMRA) and luminescent material (for example, acridinium ester).

[0068] As the nucleic acid fragment in step (1), nucleic acid purified / extracted by a known purification method or a commercially available product can be used. Examples of known purification methods include extraction with a phenol / chloroform mixture, alcohol precipitation, column purification, filtration using a filter, and agarose gel electrophoresis.

[0069] The size of the nucleic acid fragment is not limited as long as it can be encapsulated in an empty AAV particle, and is generally 5 kb or less. The nucleic acid fragment in step (1) does not contain the natural complete sequence of the AAV genome, and lacks the AAV Rep gene sequence and / or the AAV Cap gene sequence. The nucleic acid fragment does not retain the natural complete ITR sequence.

[0070] (B) Step of introducing nucleic acid into cells

[0071] The nucleic acid fragment in step (1) is introduced into the cell producing the empty particles of AAV. Examples of cells into which the nucleic acid fragment is introduced include various eukaryotic cells, such as mammalian cells, including mouse cells and primate cells (e.g., human cells), and insect cells. As used herein, cells producing empty particles of AAV or encapsulated nucleic acids therein may also be referred to as packaging cells or production cells. Suitable examples of mammalian cells include, but are not limited to, primary cells and cell lines. Suitable examples of cell lines include HEK293 cells, 293EB cells, COS cells, HeLa cells, Vero cells, 3T3 mouse fibroblasts, C3H10T1 / 2 fibroblasts, CHO cells, and cells derived from these cells. Suitable examples of insect cells include, but are not limited to, primary cells and cell lines. Suitable examples of cell lines include Sf9 cells and cell lines derived therefrom.

[0072] As cells producing empty particles, cells expressing AAV rep gene products and cap gene products are used. These gene products can be encoded by the AAV rep gene and cap gene stably integrated into the cell genome, and can be encoded by the vector introduced into the cell before, at the same time or after the nucleic acid fragment is introduced. When the rep gene and the cap gene are encoded by a vector, the rep gene and the cap gene can be encoded by a single vector or a separate vector. The rep gene and the cap gene can be sequences of any AAV serotype (e.g., serotype 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11). In addition, the rep gene and the cap gene can be sequences derived from the same serotype, or can be sequences derived from different serotypes.

[0073] The vector encoding the rep gene and the cap gene can be an expression vector suitable for the cell into which the vector is introduced, as long as the cell can produce empty particles. Examples of vectors include viral vectors, plasmid vectors, cosmid vectors, and artificial chromosomes. When necessary, a plasmid vector can be a vector that can be maintained in an additional manner. The vector can be placed under the control of a promoter and a terminator in a suitable expression system so that the rep and cap genes can be expressed in the cell. The expression system for nucleic acids is a system comprising at least one group of expression control elements required for gene expression in a functional state. Examples of expression control elements include promoters and terminators, and when necessary, enhancers and poly (A) signals.

[0074] Auxiliary functions can be further introduced into the cells that produce empty particles. Auxiliary functions are also called helper virus functions or accessory functions. For the introduction of auxiliary functions, although adenovirus is generally used, viruses such as herpes simplex virus type 1 or type 2 and vaccinia virus can also be used. When using viruses, cells are infected by viruses that serve as helper viruses. For example, because only the expression of early genes of adenovirus is required for the packaging of AAV particles, adenoviruses that do not express late genes can be used. Adenovirus mutants lacking late gene expression (e.g., ts100K or ts149 adenovirus mutants) can be used. Alternatively, nucleic acids required for helper virus functions separated from helper viruses can be used to prepare nucleic acid constructs that provide helper virus functions, and nucleic acid constructs can be introduced into cells. The construct that provides helper virus functions contains nucleotide sequences for providing one or more helper virus functions, including E1 gene regions, E2A gene regions, E4orf6 genes, and genes encoding VA RNA, and is provided to host cells in the form of plasmids, bacteriophages, transposons, cosmids, or another virus.

[0075] For introducing the nucleic acid fragment prepared in step (1) into cells, for example, the calcium phosphate method, lipofection method, DEAE dextran method, polyethyleneimine method, electroporation method, direct microinjection method, high-speed microparticle gun, etc. can be used. Commercially available reagents such as TransIT (registered trademark)-293 Reagent (manufactured by Mirus), TransIT (registered trademark)-2020 (manufactured by Mirus), Lipofectamine 2000 Reagent (manufactured by Life Technologies), Lipofectamine 2000CD Reagent (manufactured by Life Technologies), FuGene (registered trademark) Transfection Reagent (manufactured by Promega), PEI max (manufactured by Cosmo Bio), etc. can also be used.

[0076] The amount of nucleic acid fragments prepared in step (1) is 10 6 The amount of the protein to be used is 1 ng to 10 μg per cell, preferably 5 ng to 1 μg, and more preferably 10 ng to 500 ng.

[0077] (C) Steps for culturing cells

[0078] Depending on the type of cells, the cells into which the nucleic acid fragments have been introduced in (B) above can be cultured under known culture conditions. As a non-limiting example, cells can be cultured under conditions of a temperature of 30 to 37° C., a humidity of 95%, and a CO concentration of 5% to 10%. Cell culture can be carried out at a temperature, humidity, and CO concentration outside the ranges mentioned above, as long as the desired cell proliferation and the generation of empty particles encapsulating nucleic acids are achieved.

[0079] As a culture medium for culture, a known culture medium can be used. Examples of culture medium include DMEM, IMDM, Ham F12 and RPMI-1640, and they are commercially available from Lonza, Thermo Fisher Scientific, Sigma-Aldrich, etc. The culture medium may be a serum-free culture medium, or may be a culture medium containing fetal bovine serum (FBS), human serum albumin, etc.

[0080] As a cell culture device (container) for cell culture, a culture dish, a flask, a bag, a large culture tank or a bioreactor can be used. The bag can preferably be a CO2 gas permeable bag for cell culture. If a large number of cells are required, a large culture tank can be used.

[0081] The culture period is not particularly limited. For example, the cells can be cultured for 12 hours to 10 days, preferably 24 hours to 7 days. During the culture process, empty particles encapsulating nucleic acids are generated in the cells and / or in the culture supernatant, that is, AAV-like particles that retain nucleic acids inside.

[0082] In the present invention, further, a step of obtaining empty particles encapsulating nucleic acids from a cell culture supernatant or a supernatant obtained by centrifugation of a suspension of cells collected and homogenized in a suitable buffer (cell homogenate) can be performed. In the present invention, the culture supernatant or cell homogenate supernatant thus obtained can be directly stored by a suitable method such as freezing until before use, or can be subjected to empty particle concentration, purification, etc. by known methods such as filter filtration or CsCl density gradient centrifugation or by using a commercially available product, and then stored by a suitable method such as freezing until before use.

[0083] (D) Empty particles and compositions encapsulating nucleic acids

[0084] The present invention provides empty particles (AAV-like particles) in which the nucleic acid fragment prepared in step (1) is encapsulated. The empty particles of the encapsulated nucleic acid of the present invention do not retain the natural complete AAV genome, and do not retain nucleic acids containing the sequences of the AAV Rep gene and / or the AAV Cap gene. Preferably, the empty particles of the encapsulated nucleic acid of the present invention do not retain the natural complete ITR sequence, and do not retain region A' and region D. Further, the empty particles of the encapsulated nucleic acid of the present invention do not have to retain the sequence of at least one region selected from region B, region B', region C and region C'. Further, the present invention provides a composition comprising the empty particles of the encapsulated nucleic acid mentioned above. The composition of the present invention is characterized in that it comprises empty particles of at least one encapsulated nucleic acid obtained by the method of the present invention.

[0085] In addition to the empty particles of the encapsulated nucleic acid as an active ingredient, the composition of the present invention may also include carriers and / or other drugs. The composition may include two or more different types of empty particles of the encapsulated nucleic acid. In this case, the empty particles of the encapsulated nucleic acid of two or more different types may include capsids derived from different viruses, etc. and / or encapsulate different types of nucleic acids. For example, the composition may include two or more empty particles of the encapsulated nucleic acid of different cells. The carrier is a material that promotes the preparation of the drug using the composition or the application of the composition to the living body, and is added within the scope of not suppressing or suppressing the effect of the composition. The example of the carrier includes but is not limited to excipients, binders, disintegrants, fillers, emulsifiers, flow-adding modifiers and lubricants. Pharmaceutically acceptable carriers are preferably used in the composition of the present invention.

[0086] The content of empty particles encapsulating nucleic acids in the composition of the present invention is not particularly limited, and is appropriately determined taking into account the type and / or effective amount of the nucleic acid contained in the particles, the cells or individuals to which the particles are applied, the method or route of application, the purpose of application, the form of the composition (including morphology and size), the type of carrier, etc.

[0087] Empty particles of the encapsulated nucleic acid of the present invention and compositions comprising empty particles can be used for gene introduction into cells or individual animals. Such gene introduction methods are also an aspect of the present invention. Gene introduction into cells can be performed by contacting the composition with cells in vitro. By administering via approaches such as intra-tissue (e.g., intramuscular), intravenous, subcutaneous or intraperitoneal administration, compositions of the present invention are administered, thereby performing gene introduction into individual animals including humans. Example

[0088] Hereinafter, the present invention will be explained more specifically with reference to Examples, to which the scope of the present invention is not limited.

[0089] Example 1: Packaging of DNA fragments into empty AAV particles by introduction - 1

[0090] (1) Preparation of DNA fragments containing AD sequences

[0091] The shRNA encoding the target human ATP5b gene, the single-stranded DNA oligonucleotide shown in SEQ ID NO: 2, and its complementary chain are chemically synthesized as the target gene. They are annealed to prepare double-stranded DNA oligonucleotides. The double-stranded DNA oligonucleotides are cloned into the cloning site of the pENTR (trademark) / U6 vector (manufactured by Thermo Fisher Scientific) to prepare a recombinant plasmid. Further, a double-stranded DNA oligonucleotide containing the AD sequence (ranging from region A to region D'61 bp: SEQ ID NO: 1) present in the ITR of the AAV2 genomic DNA, and having the recognition sequence of the restriction enzymes SalI and KpnI at both ends, is prepared by chemically synthesizing each chain of the double-stranded DNA oligonucleotide, and then annealing the two chains. This double-stranded DNA fragment is inserted between the SalI site and the KpnI site upstream of the U6 promoter in the recombinant plasmid to prepare ATP5b shRNA plasmid DNA (plasmid AD+). This plasmid contains the AD sequence, U6 promoter sequence, shRNA sequence and Pol III terminator sequence in order from the 5' end to the 3' end. A control plasmid DNA (plasmid AD-) without the AD sequence was also prepared. These plasmid DNAs were subjected to sequencing analysis and confirmed to have the expected sequence.

[0092] PCR was performed using plasmid DNA as a template and M13 forward (-20) primer and M13 reverse primer (Thermo Fisher Scientific) to amplify DNA fragment (PCR product AD +) and DNA fragment (PCR product AD-). The PCR reaction solution was purified using a PCR purification kit (QIAGEN) and subjected to sequencing analysis for sequence confirmation.

[0093] (2) Introducing into 293EB cells

[0094] Using the plasmid DNA and DNA fragment obtained in Example 1-(1), pAAV2 / 9 (SEQ ID NO: 3) as a plasmid expressing AAV9 Cap and AAV2 Rep, and pAd5N (Agilent Technologies) as a helper plasmid, 1 × 10 8293EB cells (WO 2012 / 144446) with 100 cells were used for transfection. The weight of the transfected plasmid DNA was adjusted to 44.8 μg. The weight of the DNA fragment was adjusted to 10.9 μg according to the molar ratio. The medium used for transfection was DMEM (serum-free) containing 1 / 100 volume of GlutaMax. After transfection, the cells were cultured at 37ºC and 5% CO2 for 5 days.

[0095] (3) Recovery of AAV-like particles

[0096] After collecting the culture supernatant of the 293EB cells cultured in Example 1-(2), DNase I was added to the supernatant to degrade free DNA. After degradation, AL buffer (manufactured by Qiagen) was added to the supernatant of empty AAV particles (AAV-like particles) containing encapsulated nucleic acid to dissolve the AAV capsid and extract the packaged DNA. The copy number ( ) of plasmid DNA and DNA fragments contained in the AAV-like particles was analyzed by quantitative PCR using U6-F primer (SEQ ID NO: 4) and U6-R primer (SEQ ID NO: 5). Figure 1 ).like Figure 1 As shown in , packaging into empty AAV particles occurs more efficiently (about 15.2 times) when transfected with a DNA fragment containing the AD sequence than when transfected with a plasmid DNA containing the AD sequence. Since such DNA fragments can be prepared in large quantities by PCR, AAV-like particles can be prepared more easily.

[0097] Example 2: Packaging of DNA fragments into empty AAV particles by introduction - 2

[0098] (1) Introducing into 293EB cells

[0099] The plasmid DNA and DNA fragment prepared in Example 1-(1) were introduced into 293EB cells at the same molar concentration. Specifically, 293EB cells were transfected and cultured in the same manner as in Example 1-(2), except that the DNA fragment was used in an amount of 1 / 4.1 (724 / 2974) of the weight of the plasmid DNA, taking into account the nucleotide lengths of the ATP5bshRNA plasmid DNA (2974 bp) and the DNA fragment (PCR product AD+) (724 bp).

[0100] (3) Recovery of AAV-like particles

[0101] After collecting the culture supernatant of 293EB cells cultured in Example 2-(1), Benzonase was added to the supernatant to degrade free DNA. The supernatant was heat-treated at 50°C for 20 minutes and then centrifuged to remove the precipitate. Further, the AAV-like particles in the supernatant were purified by cesium chloride density gradient centrifugation. In the same manner as in Example 1-(3), the copy numbers of plasmid DNA and DNA fragments contained in the obtained AAV-like particles were analyzed by quantitative PCR ( Figure 2 ).like Figure 2 As shown in , even in the case where the plasmid DNA and the DNA fragment were used at the same molar concentration, packaging into empty AAV particles occurred more efficiently (about 4.6 times) when transfecting with a DNA fragment containing the AD sequence than when transfecting with a plasmid DNA containing the AD sequence.

[0102] Example 3: Cell transduction by AAV-like particles

[0103] The AAV-like particles containing plasmid (AD+) or DNA fragment (PCR product AD+) prepared in Example 1-(3) were cultured at 1.0×10 6 vg / cell was infected into HEK293 cells. Three days after infection, RNA was extracted from HEK293 cells using RNeasy Mini Kit (manufactured by QIAGEN). The expression level of ATP5b was analyzed by RT-PCR using primers hATP5b-F (SEQ ID NO: 6) and hATP5b-R (SEQ ID NO: 7). Figure 3 ).like Figure 3 As shown in , more knockdown of ATP5b gene expression was observed in cells infected with AAV-like particles containing DNA fragments compared to cells infected with AAV-like particles containing plasmid DNA.

[0104] Example 4: Packaging of modified nucleic acid to which AD sequence is added - 1

[0105] (1) Preparation of oligonucleotides

[0106] The packaging of antisense oligonucleotides targeting the fluorescent protein ZsGreen gene sequence and containing modified nucleic acids was performed. First, the AD sequence (SEQ ID NO: 1) was combined with the 3' end of the antisense sequence AO (SEQ ID NO: 12) of the ZsGreen gene to synthesize an oligonucleotide. The bonds between the nucleotides in the antisense sequence and the bonds between the antisense sequence and the AD sequence are phosphorothioate bonds (PS bonds), and the nucleotides at positions 1, 2, 3, 13 and 14 are LNA. The oligonucleotide and the separately synthesized oligonucleotides (complementary-AD, SEQ ID NO: 18) complementary to the AD sequence and composed of naturally occurring nucleotides were annealed to prepare modified oligonucleotides (No. 1). Further, a modified oligonucleotide (No. 2) in which the AD sequence was combined with the 5' end of the antisense sequence was prepared. In addition, antisense oligonucleotides (No. 3 and No. 4) in which the antisense sequence in oligonucleotides No. 1 and No. 2 was replaced with a negative control sequence AO-c (SEQ ID NO: 13) were prepared, and antisense oligonucleotides (No. 5 and No. 6) in which the AD sequence in oligonucleotides No. 1 and No. 2 was replaced with a missense AD sequence (SEQ ID NO: 14) were prepared. In addition, a single-stranded oligonucleotide (No. 7) consisting only of the antisense sequence AO and a single-stranded oligonucleotide (No. 8) consisting only of the negative control sequence AO-c were prepared. The structures of these oligonucleotides are shown in Figure 6 middle.

[0107] (2) Introduction into 293EB cells and recovery of AAV-like particles

[0108] Using oligonucleotide No. 1-8 obtained in Example 4-(1) and plasmid pAAV2 / 9 and plasmid pAd5N, 1 × 10 8 293EB cells with 100 cells. Oligonucleotides were transfected at concentrations of 0.1, 1, and 10 nM. The medium used for transfection was DMEM (serum-free) containing 1 / 100 volume of GlutaMax. After transfection, cells were cultured at 37ºC and 5% CO2 for 5 days.

[0109] After collecting the culture supernatant of 293EB cells, DNase I was added to the supernatant to degrade free DNA. After degradation, AL buffer (manufactured by Qiagen) was added to the supernatant containing empty AAV particles (AAV-like particles) containing encapsulated nucleic acid to dissolve the AAV capsid and extract the packaged DNA. The copy number of the oligonucleotide contained in the AAV-like particles was analyzed by quantitative PCR using ITR-F primers (SEQ ID NO: 15) and ITR-R primers (SEQ ID NO: 16). Figure 7 ).like Figure 7 As shown in , oligonucleotides containing an AD sequence are packaged into empty AAV particles depending on the concentration of the oligonucleotide. It was shown that packaging occurs more efficiently when the AD sequence is attached to the 3' end of the oligonucleotide.

[0110] Example 5: Packaging of DNA fragments into empty AAV particles by introduction - 3

[0111] (1) Preparation of oligonucleotides

[0112] In order to be used in exon skipping therapy for Duchenne muscular dystrophy (DMD), antisense oligonucleotides were packaged into empty AAV particles, which induced exon 23 skipping in the dystrophin gene in DMD model mice. First, the AD sequence (SEQ ID NO: 1) was combined with the 3' end of the antisense sequence AO4 (SEQ ID NO: 17) of the mouse dystrophin gene to synthesize a single-stranded oligonucleotide (SeqA-AD-F). In addition, the complementary sequence of the AD sequence (complementary-AD, SEQ ID NO: 18) was combined with the 3' end of the antisense sequence AO4 (SEQ ID NO: 17) to synthesize a single-stranded oligonucleotide (SeqA-asAD). The missense AD sequence (SEQ ID NO: 14) was combined with the 3' end of the antisense sequence AO4 (SEQ ID NO: 17) to synthesize a single-stranded oligonucleotide (SeqA-scrAD). In addition, the oligonucleotide complementary to the AD sequence (complementary-AD, SEQ ID NO: 18) and the oligonucleotide SeqA-AD-F, which were synthesized separately, were annealed to prepare an oligonucleotide (AD) in which the AD sequence region was double-stranded and the antisense sequence region was single-stranded. The structures of these oligonucleotides are shown in Figure 8 middle.

[0113] (2) Introduction into 293EB cells and recovery of AAV-like particles

[0114] Using the oligonucleotide obtained in Example 5-(1) and plasmid pAAV2 / 9 and plasmid pAd5N, 1.25 × 10 8 293EB cells with 100 cells. The transfection oligonucleotide was at a concentration of 30 nM. The medium used for transfection was DMEM (serum-free) containing 1 / 100 volume of GlutaMax. After transfection, cells were cultured at 37ºC and 5% CO2 for 5 days.

[0115] After collecting the culture supernatant of 293EB cells, AAV-like particles were purified using AAVpro (registered trademark) Concentrator (manufactured by Takara Bio Inc.). The copy number of the oligonucleotide contained in the AAV-like particles was analyzed by quantitative PCR using ITR-F primer (SEQ ID NO: 15) and ITR-R primer (SEQ ID NO: 16). Figure 8 ).like Figure 8 As shown in , single-stranded oligonucleotides containing AD sequences and / or complementary sequences to AD sequences are packaged into empty AAV particles.

[0116] Industrial Applicability

[0117] According to the present invention, a simpler and more effective method for encapsulating nucleic acid into empty particles is provided. Empty particles of encapsulated nucleic acid produced by the method of the present invention and compositions comprising empty particles of encapsulated nucleic acid as active ingredients can be used as gene introduction means in the research or clinical practice fields of gene therapy.

[0118] Sequence Listing Free Text

[0119] SEQ ID NO: 1: AD' region sequence

[0120] SEQ ID NO: 2: ATP5b shRNA sequence

[0121] SEQ ID NO: 3: pAAV2 / 9 vector sequence

[0122] SEQ ID NO: 4: U6-F Primer

[0123] SEQ ID NO: 5: U6-R Primer

[0124] SEQ ID NO: 6: HATP5b-F

[0125] SEQ ID NO: 7: hATP5b-R

[0126] SEQ ID NO: 8: A' region sequence

[0127] SEQ ID NO: 9: A region sequence

[0128] SEQ ID NO: 10: D' region sequence

[0129] SEQ ID NO: 11: D region sequence

[0130] SEQ ID NO: 12: Antisense sequence AO

[0131] SEQ ID NO: 13: Antisense sequence AO-c

[0132] SEQ ID NO: 14: Missense AD sequence

[0133] SEQ ID NO: 15: ITR Primer-F

[0134] SEQ ID NO: 16: ITR Primer-R

[0135] SEQ ID NO: 17: Antisense sequence AO4

[0136] SEQ ID NO: 18: complementary AD sequence. <110> NIPPON MEDICAL SCHOOL FOUNDATION TAKARA BIO INC. <120> Methods for producing AAV hollow particles encapsulating nucleic acids <130> 675588 <150> JP2019-124647 <151> 2019-07-03 <160> 18 <170> PatentIn version 3.5 <210> 1 <211> 61 <212> DNA <213> Artificial sequence <220> <223> AD' region sequence <400> 1 gcctcagtga gcgagcgagc gcgcagagag ggagtggcca actccatcac taggggttcc 60 t 61 <210> 2 <211> 59 <212> DNA <213> Artificial sequence <220> <223> ATP5b shRNA sequence <400> 2 caccggctga ggctccagag ttcatggaaa cgaatttcca tgaactctgg agcctcagc 59 <210> 3 <211> 7389 <212> DNA <213> Artificial sequence <220> <223> pAAV2 / 9 vector <400> 3 tcgaggacaa ccttagtgaa ggaattcgcg agtggtgggc tttgaaacct ggagcccctc 60 aacccaaggc aaatcaacaa catcaagaca acgctcgagg tcttgtgctt ccgggttaca 120 aataccttgg acccggcaac ggactcgaca agggggagcc ggtcaacgca gcagacgcgg 180 cggccctcga gcacgacaag gcctacgacc agcagctcaa ggccggagac aacccgtacc 240 tcaagtacaa ccacgccgac gccgagttcc aggagcggct caaagaagat acgtcttttg 300 ggggcaacct cgggcgagca gtcttccagg ccaaaaagag gcttcttgaa cctcttggtc 360 tggttgagga agcggctaag acggctcctg gaaagaagag gcctgtagag cagtctcctc 420 aggaaccgga ctcctccgcg ggtattggca aatcgggtgc acagcccgct aaaaagagac 480 tcaatttcgg tcagactggc gacacagagt cagtcccaga ccctcaacca atcggagaac 540 ctcccgcagc cccctcaggt gtgggatctc ttacaatggc ttcaggtggt ggcgcaccag 600 tggcagacaa taacgaaggt gccgatggag tgggtagttc ctcgggaaat tggcattgcg 660 attcccaatg gctgggggac agagtcatca ccaccagcac ccgaacctgg gccctgccca 720 cctacaacaa tcacctctac aagcaaatct ccaacagcac atctggagga tcttcaaatg 780 acaacgccta cttcggctac agcaccccct gggggtattt tgacttcaac agattccact 840 gccacttctc accacgtgac tggcagcgac tcatcaacaa caactgggga ttccggccta 900 agcgactcaa cttcaagctc ttcaacattc aggtcaaaga ggttacggac aacaatggag 960 tcaagaccat cgccaataac cttaccagca cggtccaggt cttcacggac tcagactatc 1020 agctcccgta cgtgctcggg tcggctcacg agggctgcct cccgccgttc ccagcggacg 1080 ttttcatgat tcctcagtac gggtatctga cgcttaatga tggaagccag gccgtgggtc 1140 gttcgtcctt ttactgcctg gaatttcc cgtcgcaaat gctaagaacg ggtaacaact tccagttcag ctacgagttt gagaacgtac ctttccatag cagctacgct cacagccaaa gcctggaccg actatgat ccactcatcg accatactt gtactatctc tcaaagacta ttaacggttc tggacagaat caacaaacgc taaaattcag tgtggccgga cccagcaaca tggctgtcca gggaagaaac tacatacctg gacccagcta ccgacaacaa cgtgtctcaa ccctgtgac tcaaacaac aacagcgaat ttgcttggcc tggagcttct tcttgggctc tcaatggacg fathercttg atgaatcctg gacctgctat ggccagccac aaagaaggag aggaccgttt ctttcctttg tctggatctt taatttttgg caaacaagga actggaagag acaacgtgga tgcggacaaa gtcatgataa ccaacgaaga agaattaa actactaacc cggtagcaac ggagtcctat ggacaagtgg ccacaaacca ccagagtgcc caagcacagg cgcagaccgg ctgggttcaa aaccaagga tacttccggg tatggtttgg caggacagag atgtgtacct gcaaggaccc atttgggcca aaattcctca cacggacggc aactttcacc 1860. cttctccgct gatgggaggg tttggaatga agcacccgcc tcctcagatc ctcatcaaaa 1920 acacacctgt acctgcggat cctccaacgg ccttcaacaa ggacaagctg aactctttca 1980 tcacccagta ttctactggc caagtcagcg tggagatcga gtgggagctg cagaaggaaa 2040 acagcaagcg ctggaacccg gagatccagt acacttccaa ctattacaag tctaataatg 2100 ttgaatttgc tgttaatact gaaggtgtat atagtgaacc ccgccccatt ggcaccagat 2160 acctgactcg taatctgtaa ttgcttgtta atcaataaac cgtttaattc gtttcagttg 2220 aactttggtc tctgcgaagg gcgaattcgt ttaaacctgc aggactagag tcctgtatta 2280 gaggtcacgt gagtgttttg cgacattttg cgacaccatg tggtcacgct gggtatttaa 2340 gcccgagtga gcacgcaggg tctccatttt gaagcgggag gtttgaacgc gcagccgcca 2400 agccgaattc tgcagatatc catcacactg gcggccgctc gactagagcg gccgccaccg 2460 cggtggagct ccagcttttg ttccctttag tgagggttaa ttgcgcgctt ggcgtaatca 2520 tggtcatagc tgtttcctgt gtgaaattgt tatccgctca caattccaca caacatacga 2580 gccggaagca taaagtgtaa agcctggggt gcctaatgag tgagctaact cacattaatt 2640 gcgttgcgct cactgcccgc tttccagtcg ggaaacctgt cgtgccagct gcattaatga 2700 atcggccaac gcgcggggag aggcggtttg cgtattgggc gctcttccgc ttcctcgctc 2760 actgactcgc tgcgctcggt cgttcggctg cggcgagcgg tatcagctca ctcaaaggcg 2820 gtaatacggt tatccacaga atcaggggat aacgcaggaa agaacatgtg agcaaaaggc 2880 cagcaaaagg ccaggaaccg taaaaaggcc gcgttgctgg cgtttttcca taggctccgc 2940 ccccctgacg agcatcacaa aaatcgacgc tcaagtcaga ggtggcgaaa cccgacagga 3000 ctataaagat accaggcgtt tccccctgga agctccctcg tgcgctctcc tgttccgacc 3060 ctgccgctta ccggatacct gtccgccttt ctcccttcgg gaagcgtggc gctttctcat 3120 agctcacgct gtaggtatct cagttcggtg taggtcgttc gctccaagct gggctgtgtg 3180 cacgaacccc ccgttcagcc cgaccgctgc gccttatccg gtaactatcg tcttgagtcc 3240 aacccggtaa gacacgactt atcgccactg gcagcagcca ctggtaacag gattagcaga 3300 gcgaggtatg taggcggtgc tacagagttc ttgaagtggt ggcctaacta cggctacact 3360 agaagcag tatttggtat ctgcgctctg ctgaagccag ttaccttcgg aaaaagagtt 3420 ggtagctctt gatccggcaa acaaaccacc gctggtagcg gtggtttttt tgtttgcaag 3480 cagcagatta cgcgcagaaa aaaaggatct caagaagatc ctttgatctt ttctacgggg 3540 tctgacgctc agtggaacga aaactcacgt taagggattt tggtcatgag attatcaaaa 3600 aggatcttca cctagatcct tttaaattaa aaatgaagtt ttaaatcaat ctaaagtata 3660 tatgagtaaa cttggtctga cagttaccaa tgcttaatca gtgaggcacc tatctcagcg 3720 atctgtctat ttcgttcatc catagttgcc tgactccccg tcgtgtagat aactacgata 3780 cgggaggct taccatctgg ccccagtgct gcaatgatac cgcgagaccc acgctcaccg 3840 gctccagatt tatcagcaat aaaccagcca gccggaaggg ccgagcgcag aagtggtcct 3900 gcaactttat ccgcctccat ccagtctatt aattgttgcc gggaagctag agtaagtagt 3960 tcgccagtta atagtttgcg caacgttgtt gccattgcta caggcatcgt ggtgtcacgc 4020 tcgtcgtttg gtatggcttc attcagctcc ggttcccaac gatcaaggcg agttacatga 4080 tcccccatgt tgtgcaaaaa agcggttagc tccttcggtc ctccgatcgt tgtcagaagt 4140 aagttggccg cagtgttatc actcatggtt atggcagcac tgcataattc tcttactgtc 4200 atgccatccg taagatgctt tctgtgactg gtgagtactc aaccaagtca ttctgagaat 4260 agtgtatgcg gcgaccgagt tgctcttgcc cggcgtcaat acgggataat accgcgccac 4320 atagcagaac tttaaaagtg ctcatcattg gaaaacgttc ttcggggcga aaactctcaa 4380 ggatcttacc gctggtgaga tccagttcga tgtaacccac tcgtgcaccc aactgatctt 4440 cagcatcttt tactttcacc agcgtttctg ggtgagcaaa aacaggaagg caaaatgccg 4500 caaaaaaggg aataagggcg acacggaaat gttgaatact catactcttc ctttttcaat 4560 attattgaag catttatcag ggttatgtc tcatgagcgg atacatattt gaatgtattt 4620 agaaaaataa acaaataggg gttccgcgca catttccccg aaaagtgcca cctaaattgt 4680 aagcgttaat attttgttaa aattcgcgtt aaatttttgt taaatcagct cattttttaa 4740 ccaataggcc gaaatcggca aaatccctta taaatcaaaa gaatagaccg agatagggtt 4800 gagtgttgtt ccagtttgga acaagagtcc actattaaag aacgtggact ccaacgtcaa 4860 agggcgaaaa accgtctatc agggcgatgg cccactacgt gaaccatcac cctaatcaag 4920 ttttttgggg tcgaggtgcc gtaaagcact aaatcggaac cctaaaggga gcccccgatt 4980 tagagcttga cggggaaagc cggcgaacgt ggcgagaaag gaagggaaga aagcgaaagg 5040 agcgggcgct agggcgctgg caagtgtagc ggtcacgctg cgcgtaacca ccacacccgc 5100 cgcgcttaat gcgccgctac agggcgcgtc ccattcgcca ttcaggctgc gcaactgttg 5160 ggaagggcga tcggtgcggg cctcttcgct attacgccag ctggcgaaag ggggatgtgc 5220 tgcaaggcga ttaagttggg taacgccagg gttttcccag tcacgacgtt gtaaaacgac 5280 ggccagtgag cgcgcgtaat acgactcact atagggcgaa ttgggtaccg ggccccccct 5340 cgatcgaggt cgacggtatc gggggagctc ggatccacta gtaacggccg ccagtgtgct 5400 ggattcggct ttatttaagc ccgagtgagc acgcagggtc tccattttga agcgggaggt 5460 ttgaacgcgc agccgccatg ccggggtttt acgagattgt gattaaggtc cccagcgacc 5520 ttgacgggca tctgcccggc atttctgaca gctttgtgaa ctgggtggcc gagaaggaat 5580 gggagttgcc gccagattct gacatggatc tgaatctgat tgagcaggca cccctgaccg 5640 tggccgagaa gctgcagcgc gactttctga cggaatggcg ccgtgtgagt aaggccccgg 5700 aggccctttt ctttgtgcaa tttgagaagg gagagagcta cttccacatg cacgtgctcg 5760 tggaaaccac cggggtgaaa tccatggttt tgggacgttt cctgagtcag attcgcgaaa 5820 aactgattca gagaatttac cgcgggatcg agccgacttt gccaaactgg ttcgcggtca 5880 caaagaccag aaatggcgcc ggaggcggga acaaggtggt ggatgagtgc tacatcccca 5940 attacttgct ccccaaaacc cagcctgagc tccagtgggc gtggactaat atggaacagt 6000 atttaagcgc ctgtttgaat ctcacggagc gtaaacggtt ggtggcgcag catctgacgc 6060 acgtgtcgca gacgcaggag cagaacaaag agaatcagaa tcccaattct gatgcgccgg 6120 tgatcagatc aaaaacttca gccaggtaca tggagctggt cgggtggctc gtggacaagg 6180 ggattacctc ggagaagcag tggatccagg aggaccaggc ctcatacatc tccttcaatg 6240 cggcctccaa ctcgcggtcc caaatcaagg tgccttggac aatgcgggaa agattatgag 6300 cctgactaaa accgcccccg actacctggt gggccagcag cccgtggagg acatttccag 6360 caatcggatt tataaaattt tggaactaaa cgggtacgat ccccaatatg cggcttccgt 6420 ctttctggga tgggccacga aaaagttcgg caagaggaac accatctggc tgtttgggcc 6480 tgcaactacc gggaagacca acatcgcgga ggccatagcc cacactgtgc ccttctacgg 6540 gtgcgttaac tggaccaatg agaactttcc cttcaacgac tgtgtcgaca agatggtgat 6600 ctggtgggag gaggggaaga tgaccgccaa ggtcgtggag tcggccaaag ccattctcgg 6660 aggaagcaag gtgcgcgtgg accagaaatg caagtcctcg gcccagatag acccgactcc 6720 cgtgatcgtc acctccaaca ccaacatgtg cgccgtgatt gacgggaact caacgacctt 6780 cgaacaccag cagccgttgc aagaccggat gttcaaattt gaactcaccc gccgtctgga 6840 tcatgacttt gggaaggtca ccaagcagga agtcaaagac tttttccggt gggcaaagga 6900 tcacgtggtt gaggtggagc atgaattcta cgtcaaaaag ggtggagcca agaaaagacc 6960 cgcccccagt gacgcagata taagtgagcc caaacgggtg cgcgagtcag ttgcgcagcc 7020 atcgacgtca gacgcggaag cttcgatcaa ctacgcggac aggtaccaaa acaaatgttc 7080 tcgtcacgtg ggcatgaatc tgatgctgtt tccctgcaga caatgcgaga gactgaatca 7140 gaattcaaat atctgcttca ctcacggtgt caaagactgt ttagagtgct ttcccgtgtc 7200 agaatctcaa cccgtttctg tcgtcaaaaa ggcgtatcag aaactgtgct acattcatca 7260 catcatggga aaggtgccag acgcttgcac tgcttgcgac ctggtcaatg tggacttgga 7320 tgactgtgtt tctgaacaat aaatgactta aaccaggtat ggctgccgat ggttatcttc 7380 cagattggc 7389 <210> 4 <211> 20 <212> DNA <213> Artificial sequence <220> <223> U6-F primer <400> 4 ggactatcat atgcttaccg 20 <210> 5 <211> 20 <212> DNA <213> Artificial sequence <220> <223> U6-R primer <400> 5 gtttcgtcct ttccacaaga 20 <210> 6 <211> twenty two <212> DNA <213> Artificial sequence <220> <223> hATP5b-F Primer <400> 6 ggtcctgaga ctttgggcag aa 22 <210> 7 <211> 20 <212> DNA <213> Artificial sequence <220> <223> hATP5b-R Primers <400> 7 cctcagcatg aatgggagca 20 <210> 8 <211> 41 <212> DNA <213> Artificial sequence <220> <223> A' region sequence <400> 8 ttggccactc cctctctgcg cgctcgctcg ctcactgagg c 41 <210> 9 <211> 41 <212> DNA <213> Artificial sequence <220> <223> A region sequence <400> 9 gcctcagtga gcgagcgagc gcgcagagag ggagtggcca a 41 <210> 10 <211> 20 <212> DNA <213> Artificial sequence <220> <223> D' region sequence <400> 10 ctccatcact aggggttcct 20 <210> 11 <211> 20 <212> DNA <213> Artificial sequence <220> <223> D region sequence <400> 11 aggaacccct agtgatggag 20 <210> 12 <211> 15 <212> DNA <213> Artificial <220> <223> Antisense sequence AO <220> <221> Modified bases <222> (1)..(3) <223> LNA <220> <221> Modified bases <222> (1)^(2) <223> Phosphorothioate bond <220> <221> Modified bases <222> (2)^(3) <223> Phosphorothioate bond <220> <221> Modified bases <222> (3)^(4) <223> Phosphorothioate bond <220> <221> Modified bases <222> (4)^(5) <223> Phosphorothioate bond <220> <221> Modified bases <222> (5)^(6) <223> Phosphorothioate bond <220> <221> Modified bases <222> (6)^(7) <223> Phosphorothioate bond <220> <221> Modified bases <222> (7)^(8) <223> Phosphorothioate bond <220> <221> Modified bases <222> (8)^(9) <223> Phosphorothioate bond <220> <221> Modified bases <222> (9)^(10) <223> Phosphorothioate bond <220> <221> Modified bases <222> (10)^(11) <223> Phosphorothioate bond <220> <221> Modified bases <222> (11)^(12) <223> Phosphorothioate bond <220> <221> Modified bases <222> (12)^(13) <223> Phosphorothioate bond <220> <221> Modified bases <222> (13)^(14) <223> Phosphorothioate bond <220> <221> Modified bases <222> (13)..(14) <223> LNA <220> <221> Modified bases <222> (14)^(15) <223> Phosphorothioate bond <400> 12 ttgatggcct gcttg 15 <210> 13 <211> 16 <212> DNA <213> Artificial <220> <223> Antisense sequence AO-c <220> <221> Modified bases <222> (1)..(3) <223> LNA <220> <221> Modified bases <222> (1)^(2) <223> Phosphorothioate bond <220> <221> Modified bases <222> (2)^(3) <223> Phosphorothioate bond <220> <221> Modified bases <222> (3)^(4) <223> Phosphorothioate bond <220> <221> Modified bases <222> (4)^(5) <223> Phosphorothioate bond <220> <221> Modified bases <222> (5)^(6) <223> Phosphorothioate bond <220> <221> Modified bases <222> (6)^(7) <223> Phosphorothioate bond <220> <221> Modified bases <222> (7)^(8) <223> Phosphorothioate bond <220> <221> Modified bases <222> (8)^(9) <223> Phosphorothioate bond <220> <221> Modified bases <222> (9)^(10) <223> Phosphorothioate bond <220> <221> Modified bases <222> (10)^(11) <223> Phosphorothioate bond <220> <221> Modified bases <222> (11)^(12) <223> Phosphorothioate bond <220> <221> Modified bases <222> (12)^(13) <223> Phosphorothioate bond <220> <221> Modified bases <222> (14)..(16) <223> LNA <220> <221> Modified bases <222> (14)..(14) <223> m5c <220> <221> Modified bases <222> (14)^(15) <223> Phosphorothioate bond <220> <221> Modified bases <222> (15)^(16) <223> Phosphorothioate bond <220> <221> Modified bases <222> (16) <223> m5c <400> 13 tagcttgtcc catctc 16 <210> 14 <211> 61 <212> DNA <213> Artificial <220> <223> Missense AD sequence <400> 14 atggcggcac ggcgtgctag cgatcacagt gccagacgtg ctctgtgaga gcggcaacag 60 c 61 <210> 15 <211> twenty one <212> DNA <213> Artificial <220> <223> ITR Primer-F <400> 15 ggaaccccta gtgatggagt t 21 <210> 16 <211> twenty one <212> DNA <213> Artificial <220> <223> ITR Primer-R <400> 16 gcctcagtga gcgagcgagc g 21 <210> 17 <211> 18 <212> DNA <213> Artificial <220> <223> Antisense sequence AO4 <400> 17 gccaaacctc ggcttacc 18 <210> 18 <211> 61 <212> DNA <213> Artificial <220> <223> Complementary AD sequence <400> 18 aggaacccct agtgatggag ttggccactc cctctctgcg cgctcgctcg ctcactgagg 60 c 61

Claims

1. A method for producing adeno-associated virus (AAV) empty particles encapsulating nucleic acid, the method comprising: include: (1) a step of preparing a linear nucleic acid fragment, wherein the linear nucleic acid fragment contains a region A sequence and a region D' sequence (AD sequence) in an AAV inverted terminal repeat (ITR) sequence or a complementary sequence to the AD sequence, and a target gene sequence, wherein the AD sequence or the complementary sequence to the AD sequence does not anneal within the molecule, (2) a step of introducing the nucleic acid fragment prepared in step (1) into cells producing empty AAV particles, and (3) A step of culturing the cells obtained in step (2).

2. The method according to claim 1, wherein the nucleic acid fragment contains an AD sequence or a complementary sequence of the AD sequence, and a target gene sequence in order from the 5' end to the 3' end.

3. The method according to claim 1, wherein the nucleic acid fragment contains the target gene sequence, and the AD sequence or the complementary sequence of the AD sequence in order from the 5' end to the 3' end.

4. The method according to claim 1, wherein the step of preparing the nucleic acid fragment comprises amplifying the nucleic acid fragment by a nucleic acid amplification reaction.

5. The method according to claim 1, wherein the cells producing empty particles are cells into which the Cap gene and Rep gene of AAV and the helper function of AAV have been introduced. The method according to claim 1 , wherein the nucleic acid fragment is a double-stranded nucleic acid or a single-stranded nucleic acid.

7. The method according to claim 1, wherein the region of the AD sequence in the nucleic acid fragment is a double-stranded nucleic acid, and the region of the target gene sequence in the nucleic acid fragment is a single-stranded nucleic acid.

8. A linear nucleic acid fragment comprising a region A sequence and a region D' sequence (AD sequence) in an AAV inverted terminal repeat (ITR) or a complementary sequence to the AD sequence, and a target gene sequence, wherein the AD sequence or the complementary sequence to the AD sequence does not anneal within the molecule.

9. The nucleic acid fragment according to claim 8, which contains an AD sequence or a complementary sequence to the AD sequence, and a target gene sequence in order from the 5' end to the 3' end.

10. The nucleic acid fragment according to claim 8, which contains the target gene sequence, and the AD sequence or the complementary sequence of the AD sequence in order from the 5' end to the 3' end. The nucleic acid fragment according to claim 8 , which is a double-stranded nucleic acid or a single-stranded nucleic acid.

12. The nucleic acid fragment according to claim 8, wherein the region of the AD sequence is a double-stranded nucleic acid, and the region of the target gene sequence is a single-stranded nucleic acid.

13. An empty AAV particle encapsulating a nucleic acid, comprising a linear nucleic acid segment according to any one of claims 8 to 12.